# A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Study · id `cardio:ct-nct03214380` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03214380](<https://clinicaltrials.gov/study/NCT03214380>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03214380

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 933 participants.

## Technical summary

Registry record NCT03214380. Randomized; double masking; primary purpose treatment. Start 2017-07-14 (actual); primary completion 2018-08-14 (actual). Results posted on 2020-03-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 933 participants (enrolled count; ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Started: 2017-07-14 (actual) (ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Primary completion: 2018-08-14 (actual) (ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Completion: 2019-03-13 (actual) (ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Results first posted: 2020-03-27 (ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Czechia; Germany; Hungary; India; Italy; Japan; Mexico; Puerto Rico; Russia; Slovakia; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT03214380, source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03214380-2020-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
- Acronym: PRONTO-T2D
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): LY900014
- Intervention (Drug): Insulin Lispro
- Intervention (Drug): Insulin Glargine
- Intervention (Drug): Insulin Degludec
- Intervention (Drug): Metformin
- Intervention (Drug): SGLT2 inhibitor
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D (`cardio:pubmed-32616612`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 431ae26f974223c4d820454d323f0457e9e2a466d981d2570478bfebc07a0813
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
